Kairos Pharma, LTD.
KAPA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KAPA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KAPA
Kairos Pharma, LTD. is a preclinical-stage biopharmaceutical company developing novel drugs targeting drug resistance and immune suppression checkpoints, with no approved products or revenue to date.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Kairos Pharma, LTD..
Kairos Pharma, LTD. is a preclinical-stage biopharmaceutical company developing novel drugs targeting drug resistance and immune suppression checkpoints, with no approved products or revenue to date.
- Kairos Pharma is developing a new class of drugs designed to target drug resistance and checkpoints of immune suppression [sec_mda · as of 2026-08-12].
- As of the latest quarterly report, the company's product candidates have not been approved as safe or effective by the FDA or any comparable foreign regulator [sec_mda · as of 2026-08-12].
- The company has not generated any revenue from product sales and has incurred significant operating losses since inception [sec_mda · as of 2026-08-12].
- As of June 30, 2026, the company reported cash and equivalents of $2.6 million, net income of -$1.4 million, and shareholders' equity of $6.3 million [sec].
What works
- The company's drug candidates target drug resistance and immune suppression checkpoints, which are key areas in oncology [sec_mda · as of 2026-08-12].
- Management believes existing cash will fund operations for at least the next 12 months, based on current assumptions [sec_mda · as of 2025-08-12].
What to weigh
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-08-12].
- Kairos Pharma has incurred significant operating losses since inception, with net losses reported in recent periods [sec_mda · as of 2026-08-12].
- The company may need additional financing to continue operations, as it expects to require further capital [sec_mda · as of 2025-08-12].
From the filings
Quoted directly from source documents.
The company's product candidates are not yet approved by regulators.
“As of the date of this Quarterly Report, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator.”
SEC MD&A · August 12, 2026
The company has no revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 12, 2026
The company has incurred significant operating losses.
“Since inception, we have incurred significant operating losses.”
SEC MD&A · August 12, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Product candidates have not been approved by FDA or any foreign regulator [sec_mda · as of 2026-08-12].
- History of losses — Significant operating losses since inception; no revenue from product sales [sec_mda · as of 2026-08-12].
- Need for additional capital — Company expects to require additional financing to fund operations [sec_mda · as of 2025-08-12].
What to watch
- Regulatory progress: any updates on FDA or foreign regulatory interactions for product candidates [sec_mda · as of 2026-08-12].
- Financial runway: cash position and any new financing rounds or partnerships [sec_mda · as of 2025-08-12].
- Clinical development: initiation or results of preclinical or clinical studies for drug candidates [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Kairos Pharma, LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kairos Pharma, LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
8.3 months
D/E 0.06 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$402K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 463,756 | $259K |
| geode capital management, llc | 111,290 | $62K |
| vanguard fiduciary trust co | 63,884 | $36K |
| two sigma investments, lp | 39,543 | $22K |
| state street corp | 24,100 | $13K |
| two sigma securities, llc | 16,247 | $9K |
| hrt financial lp | 21,575 | $12 |
| citigroup inc | 10 | $6 |
Short Interest
as of May 21, 2026- % of float
- 0.9%
- Days to cover
- 1.4
- Shares short
- 125,693
- Daily short volume (May 4, 2026)
- 12.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KAPA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Kairos Pharma, LTD.?
Kairos Pharma, LTD. is a preclinical-stage biopharmaceutical company developing novel drugs targeting drug resistance and immune suppression checkpoints, with no approved products or revenue to date.
What is Kairos Pharma, LTD.'s lead drug candidate?
Kairos Pharma, LTD.'s most advanced tracked candidate is env 105 (Phase 2) for prostate cancer and non-small cell lung cancer.
Who is the CEO of Kairos Pharma, LTD.?
Dr. John S. Yu M.D., Ph.D. is the chief executive officer of Kairos Pharma, LTD. (KAPA).
Where is Kairos Pharma, LTD. headquartered?
Kairos Pharma, LTD. (KAPA) is headquartered in Los Angeles, CA, United States.
What therapeutic areas does Kairos Pharma, LTD. focus on?
Kairos Pharma, LTD. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.